Humacyte, Inc.
HUMA$280M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaDURHAM
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 10, 2026
7wMarket Overview
Stock performance and key metrics
HUMA News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Human Acellular Vessel (HAV)
Renal Failure
Acellular Tissue Engineered Vessel (ATEV)
End Stage Renal Disease (ESRD)
HAV
Renal Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Human Acellular Vessel (HAV) | Phase 3 | Renal Failure | - | - |
Acellular Tissue Engineered Vessel (ATEV) | Phase 3 | End Stage Renal Disease (ESRD) | - | - |
HAV | Phase 2 | Renal Failure | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply